SPA
SLNO

Sherbrooke Park Advisers’s Soleno Therapeutics SLNO Stock Holding History

Sherbrooke Park Advisers’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,830
Closed -$559K – 757
2025
Q1 		$559K Buy
+7,830
New +$381K 0.26% 106

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Sherbrooke Park Advisers's SLNO Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 7,830 shares — an estimated $559K sold.

Sherbrooke Park Advisers first reported a position in SLNO in Q1 2025 and held it in 1 quarter. The position peaked at $559K in Q1 2025. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

  • Sherbrooke Park Advisers reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 7,830 Soleno Therapeutics shares in Q2 2025, an estimated $559K.
  • Sherbrooke Park Advisers first reported a position in Soleno Therapeutics in Q1 2025 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Soleno Therapeutics position peaked at $559K in Q1 2025.
  • 233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.